649 related articles for article (PubMed ID: 29992492)
41. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
42. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
43. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
[TBL] [Abstract][Full Text] [Related]
44. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer.
Boysen AK; Pallisgaard N; Andersen CSA; Spindler KG
Acta Oncol; 2020 Dec; 59(12):1424-1429. PubMed ID: 32790489
[TBL] [Abstract][Full Text] [Related]
45. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
46. Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer.
Al Naji H; Winter JM; Pedersen SK; Roy A; Byrne SE; Young GP; Symonds EL
Biomark Insights; 2024; 19():11772719241232870. PubMed ID: 38426070
[TBL] [Abstract][Full Text] [Related]
47. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
48. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
49. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
50. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.
Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J
Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496
[TBL] [Abstract][Full Text] [Related]
51. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.
Ng SB; Chua C; Ng M; Gan A; Poon PS; Teo M; Fu C; Leow WQ; Lim KH; Chung A; Koo SL; Choo SP; Ho D; Rozen S; Tan P; Wong M; Burkholder WF; Tan IB
Sci Rep; 2017 Jan; 7():40737. PubMed ID: 28102343
[TBL] [Abstract][Full Text] [Related]
52. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
[TBL] [Abstract][Full Text] [Related]
53. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
54. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
Cells; 2019 May; 8(6):. PubMed ID: 31142037
[TBL] [Abstract][Full Text] [Related]
55. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
Adams AM; Vreeland TJ; Newhook TE
J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
[TBL] [Abstract][Full Text] [Related]
56. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
57. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
58. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
59. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
Zheng J; Qin C; Wang Q; Tian D; Chen Z
EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
[TBL] [Abstract][Full Text] [Related]
60. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
